JP2016539105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539105A5 JP2016539105A5 JP2016527424A JP2016527424A JP2016539105A5 JP 2016539105 A5 JP2016539105 A5 JP 2016539105A5 JP 2016527424 A JP2016527424 A JP 2016527424A JP 2016527424 A JP2016527424 A JP 2016527424A JP 2016539105 A5 JP2016539105 A5 JP 2016539105A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cells
- composition according
- patient
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- 210000001808 exosome Anatomy 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000008365 aqueous carrier Substances 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000002476 tumorcidal effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899066P | 2013-11-01 | 2013-11-01 | |
| US61/899,066 | 2013-11-01 | ||
| PCT/US2014/062695 WO2015066054A1 (en) | 2013-11-01 | 2014-10-28 | Tumoricidal and antimicrobial compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186716A Division JP6870053B2 (ja) | 2013-11-01 | 2019-10-10 | 殺腫瘍性および抗菌性の組成物ならびに方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539105A JP2016539105A (ja) | 2016-12-15 |
| JP2016539105A5 true JP2016539105A5 (https=) | 2017-12-07 |
| JP6603216B2 JP6603216B2 (ja) | 2019-11-06 |
Family
ID=53005034
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527424A Active JP6603216B2 (ja) | 2013-11-01 | 2014-10-28 | 殺腫瘍性および抗菌性の組成物ならびに方法 |
| JP2019186716A Active JP6870053B2 (ja) | 2013-11-01 | 2019-10-10 | 殺腫瘍性および抗菌性の組成物ならびに方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186716A Active JP6870053B2 (ja) | 2013-11-01 | 2019-10-10 | 殺腫瘍性および抗菌性の組成物ならびに方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US10258649B2 (https=) |
| EP (4) | EP4134085B1 (https=) |
| JP (2) | JP6603216B2 (https=) |
| KR (5) | KR102329796B1 (https=) |
| CN (3) | CN121466286A (https=) |
| AU (1) | AU2014342477B2 (https=) |
| CA (1) | CA2927977C (https=) |
| ES (1) | ES2935906T3 (https=) |
| WO (1) | WO2015066054A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4134085B1 (en) | 2013-11-01 | 2026-04-29 | ImmunityBio, Inc. | Tumoricidal and antimicrobial compositions and methods |
| EP4424326A3 (en) | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| WO2017100709A1 (en) * | 2015-12-09 | 2017-06-15 | Nant Holdings Ip, Llc | Compositions and methods for treatment of her2 positive metastatic breast cancer |
| US11142552B2 (en) * | 2016-07-19 | 2021-10-12 | National Institute Of Plant Genome Research | Protein against fungal pathogens |
| WO2018064594A2 (en) * | 2016-09-29 | 2018-04-05 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
| CN108324735B (zh) * | 2017-01-20 | 2024-02-09 | 李莉 | 用于疾病治疗的胞外体制剂及其应用 |
| US20200163993A1 (en) * | 2017-05-09 | 2020-05-28 | Saint Louis University | Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes |
| US20210040451A1 (en) * | 2018-01-31 | 2021-02-11 | Nantkwest, Inc. | Use of 5% human albumin in wash and harvest media |
| CN108815186A (zh) * | 2018-06-14 | 2018-11-16 | 上海鸣大生物科技有限公司 | 一种治疗hpv持续感染引起疾病的药物及制备方法与应用 |
| EP4013782A4 (en) * | 2019-08-12 | 2023-12-27 | Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. | IMMUNE COMPOSITION COMPRISING A RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYPEPTIDE G |
| WO2025221993A1 (en) | 2024-04-18 | 2025-10-23 | Immunitybio, Inc. | Compositions and methods for producing il-16 |
| US20260027155A1 (en) | 2024-07-23 | 2026-01-29 | Immunitybio, Inc. | Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7267398A (en) * | 1997-04-30 | 1998-11-24 | Hans Klingemann | Natural killer cell lines and methods of use |
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| US8067044B2 (en) | 2004-02-13 | 2011-11-29 | Cognis France S.A.S. | Cosmetic compositions containing an extract of leaves of the Castanea sativa plant and cosmetic treatments |
| WO2006004518A1 (en) | 2004-07-02 | 2006-01-12 | Avaris Ab | Method for the genetic activation of cells and uses of said cells |
| DE602005016683D1 (de) | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| CN102014934B (zh) | 2008-02-22 | 2014-08-20 | 新加坡科技研究局 | 间充质干细胞颗粒 |
| WO2012013204A1 (en) * | 2010-07-28 | 2012-02-02 | Canvax Biotech Sl | Novel ultrasensitive cell based sensors and uses thereof |
| KR101298012B1 (ko) | 2011-02-08 | 2013-08-26 | (주)차바이오앤디오스텍 | 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물 |
| US20150212064A1 (en) * | 2011-08-12 | 2015-07-30 | The Childrens's Hospital Of Philadelphia | Degranulation indicator and methods of use thereof |
| EP4134085B1 (en) | 2013-11-01 | 2026-04-29 | ImmunityBio, Inc. | Tumoricidal and antimicrobial compositions and methods |
| JP2020524164A (ja) | 2017-06-20 | 2020-08-13 | ナントクエスト インコーポレイテッド | Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法 |
| KR20200035999A (ko) | 2017-08-04 | 2020-04-06 | 난트케이웨스트, 인크. | Nk-92 세포를 이용한 백혈병의 치료 및 억제 |
-
2014
- 2014-10-28 EP EP22197465.2A patent/EP4134085B1/en active Active
- 2014-10-28 EP EP26153551.2A patent/EP4707383A2/en active Pending
- 2014-10-28 WO PCT/US2014/062695 patent/WO2015066054A1/en not_active Ceased
- 2014-10-28 KR KR1020167014198A patent/KR102329796B1/ko active Active
- 2014-10-28 KR KR1020217037585A patent/KR102476640B1/ko active Active
- 2014-10-28 AU AU2014342477A patent/AU2014342477B2/en active Active
- 2014-10-28 KR KR1020237018562A patent/KR20230085215A/ko not_active Ceased
- 2014-10-28 US US15/032,518 patent/US10258649B2/en active Active
- 2014-10-28 CN CN202511509108.8A patent/CN121466286A/zh active Pending
- 2014-10-28 CN CN202510641320.3A patent/CN120501764A/zh active Pending
- 2014-10-28 KR KR1020257021166A patent/KR20250099421A/ko active Pending
- 2014-10-28 CA CA2927977A patent/CA2927977C/en active Active
- 2014-10-28 CN CN201480068072.8A patent/CN105848662A/zh active Pending
- 2014-10-28 KR KR1020227036373A patent/KR20220147705A/ko not_active Ceased
- 2014-10-28 JP JP2016527424A patent/JP6603216B2/ja active Active
- 2014-10-28 EP EP20159448.8A patent/EP3701957B1/en active Active
- 2014-10-28 EP EP14858835.3A patent/EP3062800B1/en active Active
- 2014-10-28 ES ES20159448T patent/ES2935906T3/es active Active
-
2018
- 2018-12-06 US US16/212,578 patent/US10646516B2/en active Active
-
2019
- 2019-02-28 US US16/289,512 patent/US10772912B2/en active Active
- 2019-02-28 US US16/289,494 patent/US10517895B2/en active Active
- 2019-02-28 US US16/289,526 patent/US11213547B2/en active Active
- 2019-10-10 US US16/598,418 patent/US11304977B2/en active Active
- 2019-10-10 JP JP2019186716A patent/JP6870053B2/ja active Active
-
2021
- 2021-11-30 US US17/539,155 patent/US11975027B2/en active Active
-
2022
- 2022-02-22 US US17/677,727 patent/US12064450B2/en active Active
-
2024
- 2024-07-17 US US18/775,316 patent/US20240366674A1/en active Pending
-
2025
- 2025-01-17 US US19/030,104 patent/US20250170181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539105A5 (https=) | ||
| ZA201900367B (en) | Formulation of a peptide vaccine | |
| MY206158A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| EP4272750A3 (en) | Protein antigens that provide protection against pneumococcal colonization and/or disease | |
| MX2021002586A (es) | Dosis unitaria de vacuna contra el dengue y administracion de esta. | |
| CA3011103A1 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| WO2009033785A3 (en) | Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| RU2016147048A (ru) | Противомикробная иммуномодуляция | |
| SA521420957B1 (ar) | FXIa تركيبة جديدة ثابتة عالية التركيز لأجسام مضادة تعمل ضد | |
| MX2020008454A (es) | Composicion inmunogenica que comprende antigenos estafilococicos. | |
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
| MX2022003051A (es) | Formulaciones para la administracion de farmacos. | |
| MX2016003783A (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv), en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante, apta para su uso farmaceutico. | |
| EA202191130A1 (ru) | Фармацевтическая композиция для лечения апластической анемии | |
| MX2020000009A (es) | Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos. | |
| FI3144002T3 (fi) | Granulosyytti-makrofagikasvutekijää (GM-CSF) tuottava T-solusäätelyaine sekä Th1/Th2-immuunitasapainon säätelijä | |
| PH12022550939A1 (en) | Chikungunya virus-like particle vaccine and methods of using the same | |
| CO2018001531A2 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina | |
| WO2019022463A3 (ko) | 면역원성시스템 및 이를 포함한 동물 백신 | |
| EA202190120A1 (ru) | Аналог циклического динуклеотида, его фармацевтическая композиция и применение | |
| PL431336A1 (pl) | Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek |